Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)

doi:10.3748/wjg.v29.i40.5593

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5753)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-9) series, Tables (1-2) series.

Item

Count

PDF

112

WORD

HTML

3177

Figures (1-9)

287

Tables (1-2)

294

Sum=3909

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

241

Download

623

Sum=864

Publishing Process of This Article

Item

Count

Browse

195

Download

596

Sum=791

Oct 28, 2023 (publication date) through Nov 14, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Scientometrics

World J Gastroenterol. Oct 28, 2023; 29(40): 5593-5617
Published online Oct 28, 2023. doi: 10.3748/wjg.v29.i40.5593

Table 1 The top ten co-cited documents

	Title	Year	Type	First author	Journal	IF (2021)	JCR	Co-citation	DOI	Impact index per article
1	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer	2012	Clinical trial	Brahmer JR	N Engl J Med	176.08	Q1	5555	10.1056/NEJMoa1200694	524.5
2	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study	2016	Clinical trial	Nanda R	J Clin Oncol	50.72	Q1	1297	10.1200/JCO.2015.64.8931	133.7
3	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis	2010	Review	Paoletti X	JAMA	157.34	Q1	604	10.1001/jama.2010.534	47.9
4	Progress in the treatment of advanced gastric cancer	2017	Review	Song ZY	Tumour Biol	3.65 (2016)	Q2	490	10.1177/1010428317714626	75.7
5	m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer	2020	Article	Zhang B	Mol Cancer	41.44	Q1	442	10.1186/s12943-020-01170-0	134.0
6	PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer	2019	Article	Kamada T	Proc Natl Acad Sci U S A	12.78	Q1	428	10.1073/pnas.1822001116	106.8
7	Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures	2019	Article	Zeng DQ	Cancer Immunol Res	12.02	Q1	418	10.1158/2326-6066.CIR-18-0436	93.7
8	PD-L1 expression in human cancers and its association with clinical outcomes	2016	Review	Wang X	Onco Targets Ther	4.35	Q2	412	10.2147/OTT.S105862	59.0
9	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer	2019	Article	Kather JN	Nat Med	87.24	Q1	400	10.1038/s41591-019-0462-y	114.0
10	The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial	2010	Clinical trial	Heiss MM	Int J Cancer	7.32	Q1	349	10.1002/ijc.25423	30.8

JCR: Journal Citation Reports; IF: Impact Factor.

Citation: Li YN, Xie B, Zhang Y, He MH, Xing Y, Mu DM, Wang H, Guo R. Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023). World J Gastroenterol 2023; 29(40): 5593-5617
URL: https://www.wjgnet.com/1007-9327/full/v29/i40/5593.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i40.5593